Mixed Urinary IncontinenceAURA-4XNCT06885931
Augmenting Urinary Reflex Activity Study 4 (Including eXtended Indications)
A study testing Pudendal neuromodulation in people with Mixed Urinary Incontinence and Stress Urinary Incontinence (SUI), run by Amber Therapeutics Ltd at 7 sites in 3 countries.
Trial summary
Exploratory safety and feasibility study of personalized adaptive pudendal neuromodulation for mixed urinary incontinence and extended indications using an implanted (Picostim™ II) system. Read more about this study
- Who is it for?
- Ages 22 years and older, women only
- Conditions the study is for
- Mixed Urinary Incontinence, Stress Urinary Incontinence (SUI), Chronic Pelvic Pain
- What is being tested?
- Pudendal neuromodulation
- Type of treatment
- Medical device
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 86 participants
- Where
- 7 sitesin 3 countries
- Study dates
- 24 Jun 2025to Jan 2030
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 22 years and older
- Women only
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Female. NB: the definition of female refers to sex at birth.
- Adult: aged ≥ 22 years (at the time of informed consent signature).
- Patient self-reports both stress and urge episodes (clinician-opinion on history taking).
- Patient has failed to respond to or could not tolerate conservative treatment as determined by the treating health care provider.
- Duration of urinary incontinence symptom ≥ 6 months prior to the screening baseline visit date.
- Able and willing to voluntarily sign informed consent form.
Show all 9Show fewer
- Able to participate in all testing and follow-up clinic visits associated with study protocol.
- Patient is mobile and able to use a toilet.
- In the opinion of the Investigator, the patient is capable of independently using the system components (after training).
Who cannot join
- Patient is pregnant, breastfeeding, or plans to become pregnant at any time in the future.
- Patient is unwilling or unable to use contraception during sexual intercourse for the duration of the study.
- In the event that patient becomes pregnant during or after the study, they are not prepared to inactivate device for the whole period of the pregnancy.
- Any significant medical condition that, in the opinion of the Investigator, is likely to interfere with study procedures, device operation, or likely to confound evaluation of study endpoints.
- History of major psychiatric or personality disorder.
- Any neurological condition that in the opinion of the investigator may interfere with normal bladder function (e.g., stroke, multiple sclerosis, Parkinson's disease, clinically significant peripheral neuropathy, or complete spinal cord injury).
Show all 32Show fewer
- Uncontrolled type I or type II diabetes (as defined by their routine care clinician or HBA1C ≥ 7.0).
- History of cancer within 5 years prior to enrolment, except for a cancer that was determined to be free of systemic cancer risk, such as basal cell carcinoma.
- Patient is taking antiplatelet and/or anticoagulant drugs including warfarin or newer alternatives (e.g., rivaroxaban, apixaban, dabigatran, edoxaban) which cannot be paused prior to surgery, or has a bleeding disorder that cannot be corrected prior to surgery.
- Any clinical reason that, in the opinion of the Investigator, may compromise patient's safety during the study.
- Currently participating in another interventional study. This excepts purely observational studies, e.g., registries.
- Patient participation in vigorous physical activities where these cannot be restricted for a period of 6 weeks post-implantation.
- Patient unwilling to stop any future participation in scuba diving below 10m. BMI ≥ 40kg/m2 or waist circumference > 127cm
- Documented history of allergic response to titanium, zirconia, polyurethane, epoxy, or silicone.
- Skin, orthopedic or neurological anatomical limitations at the site of implant that could prevent successful placement of an electrode or IPG. This includes active perineal sepsis or perianal sepsis (e.g., anal fistula and pilonidal sinus).
- Knowledge of planned MRIs, diathermy, medical microwave exposure, high output ultrasonic exposure, or medical RF energy exposure.
- Implantable neurostimulator or antennae, pacemaker or defibrillator in-situ (anywhere in body).
- Known diagnosis of interstitial cystitis or bladder pain syndrome as defined by either AUA or EAU guidelines. Diagnosis of any other chronic pelvic or regional pain syndrome
- Documented bladder emptying syndrome including neurogenic bladder.
- Known abnormal post void residual (> 100 ml).
- Any prolapse (symptomatic or asymptomatic) currently at or below the hymenal level Known urinary tract mechanical obstruction such as urethral stricture and/or bladder neck contracture.
- Current symptomatic urinary tract infection (UTI) or more than 3 culture-proven UTIs in past year.
- Current diagnosis of vesicoureteral reflux
- Current diagnosis of bladder stones
- History of bladder tumour (benign or malignant) -Suspected or proven pudendal nerve entrapment syndrome. In patients with co- existent chronic pelvic pain and urinary incontinence symptoms, Nantes criteria will be used for screening. Patients meeting essential criteria will be excluded from the study.
- Suspected or proven severe pudendal nerve damage at discretion of clinician with or without specialist investigations
- Any previous experience of pudendal nerve stimulation using an implanted lead.
- Previous failure of SNM therapy (based on implantation; failed test phase is not an exclusion)
- Major previous urethral or bladder surgery (excisional or reconstructive) at discretion of investigator
- SUI surgery e.g. urethral slings, tapes, and bulking agents colposuspension within last 2 years; > 2 years at discretion of investigator
- Prolapse surgery e.g. colposuspension / colporrhaphy within last 12 months with current confirmation via pelvic exam of no recurrence > or = to Stage 2 pelvic organ prolapse
- Previous use of bladder botox injections within last 6 months
Trial locations and contacts
7 sites in 3 countries. Contact the study team or a site near you to ask about taking part.
7 sites in 3 countries
Belgium3 sites, 3 recruiting
- Recruiting
Universitair Ziekenhuis Antwerpen
Edegem, 655, 2650
Tim Brits, Doctor of Medicine, +32 3 821 30 00, urologie@uza.be
- Recruiting
Ghent University Hospital
Ghent, 9000
Francois Herve, Professor/ Doctor of Medicine, +3293320839, Francois.Herve@uzgent.be
- Recruiting
UZ Leuven
Leuven, Herestraat 49, 3000
Frank Van der Aa, Professor/ Doctor of Medicine, +32 16 34 83 45, frank.vanderaa@uzleuven.be
United Kingdom3 sites, 3 recruiting
- Recruiting
Southmead Hospital
Bristol
Victoria Garner, 01174148109, victoria.garner@nbt.nhs.uk
- Recruiting
University College London Hospital
London, NW1 2BU
Mahreen Pakzad, Doctor of Medicine, Mahreen.pakzad@nhs.net
- Not yet recruiting
Guy's Hospital
London
Arun Sahai, 07956394943, Arun.sahai@nhs.net
Netherlands1 site, 1 recruiting
- Recruiting
Maastricht UMC
Maastricht, 6229 HX
Martijn Smits, Doctor of Medicine, +31 (0)6 29 65 22 47, mac.smits@mumc.nl
About this study
Official title: Exploratory Safety and Feasibility Study of Personalized Adaptive Pudendal Neuromodulation for Mixed Urinary Incontinence and Extended Indications Using an Implanted (Picostim IITM) System
Exploratory safety and feasibility study of personalized adaptive pudendal neuromodulation for mixed urinary incontinence and extended indications using an implanted (Picostim™ II) system.
- Conditions
- Mixed Urinary Incontinence, Stress Urinary Incontinence (SUI), Chronic Pelvic Pain, Urge Urinary Incontinence
- Being tested
- Pudendal neuromodulation
- Medical subject headings
- Urinary Incontinence, Stress, Urinary Incontinence, Urge
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Pudendal neuromodulationDevice
In this feasibility study, all subjects will receive the Amber UI system.
| Study group | Role | What they receive |
|---|---|---|
| Cohort A | Experimental | Mixed Urinary Incontinence cohort Receives: Device: Pudendal neuromodulation |
| Cohort B | Experimental | Extended indications cohort (Stress Urinary Incontinence, Urge Urinary Incontinence, Chronic Pelvic Pain, AURA-2) Receives: Device: Pudendal neuromodulation |
What is being measured
The primary outcome is the main question the study is designed to answer.
Summative rates of procedural and device related adverse events and device deficiencies.
Measured: 12 months
Urinary Distress Inventory score change
Score minimum 0 to maximum 100. Lower score is better outcome.
Measured: 6 months
Proportion of participants requiring surgical reintervention.
Measured: 12 months
Secondary outcomes (9)
Urinary Distress Inventory (total, total Mixed Urinary Incontinence) score change
Score minimum 0 to maximum 100. Lower score is better outcome.
Measured: 12 months
3-day voiding diary number of events
Fewer events is better outcome.
Measured: 12 months
24-hour pad test weight change
Lower weight is better outcome.
Measured: 12 months
The International Consultation on Incontinence Questionnaire score change
Score minimum 0 to maximum 21. Lower score is better outcome.
Measured: 12 months
Patient Global Impression of Improvement score change
Score minimum 0 to maximum 7. Lower score is better outcome.
Measured: 12 months
General Anxiety Disorder score change
Score minimum 0 to maximum 21. Lower score is better outcome.
Measured: 12 months
Patient Health Questionnaire 9 score change
Score minimum 0 to maximum 27. Lower score is better outcome.
Measured: 12 months
World Health Organization Disability Assessment Schedule score change
Score minimum 0 to maximum 100. Lower score is better outcome.
Measured: 12 months
European Quality of Life 5 Dimension Questionnaire score change.
Score minimum 5 to maximum 25. Higher score is a better outcome.
Measured: 12 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted20 Mar 2025
- Study start24 Jun 2025
- Primary completionJun 2027 (estimated)
- Study completionJan 2030 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Mixed Urinary IncontinenceStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Non-randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Enrolment
- 86 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Amber Therapeutics Ltd
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06885931
- Sponsor's protocol ID
- TS-01529
- Acronym
- AURA-4X
- Status last verified
- Mar 2026
- First submitted
- 6 Mar 2025
- Last updated
- 15 May 2026
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 15 May 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Exploratory Safety and Feasibility Study of Personalized Adaptive Pudendal Neuromodulation for Mixed Urinary Incontinence and Extended Indications Using an Implanted (Picostim IITM) System
- ClinicalTrials.gov ID
- NCT06885931
- Acronym / sponsor ID
- AURA-4X / TS-01529
- Conditions
- Mixed Urinary Incontinence, Stress Urinary Incontinence (SUI), Chronic Pelvic Pain, Urge Urinary Incontinence
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 86 participants (estimated)
- Lead sponsor
- Amber Therapeutics LtdIndustry (pharma, biotech, devices)
- Study start
- 24 Jun 2025 (actual)
- Primary completion
- Jun 2027 (estimated)
- Study completion
- Jan 2030 (estimated)
- First posted
- 20 Mar 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Exploratory safety and feasibility study of personalized adaptive pudendal neuromodulation for mixed urinary incontinence and extended indications using an implanted (Picostim™ II) system.
Study design
- Primary purpose
- Treatment
- Allocation
- Non-randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Cohort A | Experimental | Device: Pudendal neuromodulationMixed Urinary Incontinence cohort |
| Cohort B | Experimental | Device: Pudendal neuromodulationExtended indications cohort (Stress Urinary Incontinence, Urge Urinary Incontinence, Chronic Pelvic Pain, AURA-2) |
Who may qualify
- Ages
- 22 years and older
- Sex
- Female only
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (9 listed)
- Female. NB: the definition of female refers to sex at birth.
- Adult: aged ≥ 22 years (at the time of informed consent signature).
- Patient self-reports both stress and urge episodes (clinician-opinion on history taking).
- Patient has failed to respond to or could not tolerate conservative treatment as determined by the treating health care provider.
- Duration of urinary incontinence symptom ≥ 6 months prior to the screening baseline visit date.
Key exclusion criteria (32 listed)
- Patient is pregnant, breastfeeding, or plans to become pregnant at any time in the future.
- Patient is unwilling or unable to use contraception during sexual intercourse for the duration of the study.
- In the event that patient becomes pregnant during or after the study, they are not prepared to inactivate device for the whole period of the pregnancy.
- Any significant medical condition that, in the opinion of the Investigator, is likely to interfere with study procedures, device operation, or likely to confound evaluation of study endpoints.
- History of major psychiatric or personality disorder.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Pudendal neuromodulationIn this feasibility study, all subjects will receive the Amber UI system. | Device | Cohort A, Cohort B |
Primary outcome
Summative rates of procedural and device related adverse events and device deficiencies.
Time frame: 12 months
Urinary Distress Inventory score change
Time frame: 6 months
Score minimum 0 to maximum 100. Lower score is better outcome.
Proportion of participants requiring surgical reintervention.
Time frame: 12 months
9 secondary outcomes
Urinary Distress Inventory (total, total Mixed Urinary Incontinence) score change
Time frame: 12 months
3-day voiding diary number of events
Time frame: 12 months
24-hour pad test weight change
Time frame: 12 months
The International Consultation on Incontinence Questionnaire score change
Time frame: 12 months
Patient Global Impression of Improvement score change
Time frame: 12 months
General Anxiety Disorder score change
Time frame: 12 months
Patient Health Questionnaire 9 score change
Time frame: 12 months
World Health Organization Disability Assessment Schedule score change
Time frame: 12 months
European Quality of Life 5 Dimension Questionnaire score change.
Time frame: 12 months
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 15 May 2026.
- Individual participant dataSharing planned: No
Related trials for Mixed Urinary Incontinence
Recruiting
Comparing the Effect of Two Types of Pelvic Floor Muscle Stimulation Devices to Improve Symptoms of Urinary Incontinence in Women.
Urinary Incontinence, Mixed Urinary Incontinence
Active, not recruiting
Pelvic Floor Rehabilitation Programme for Women With Urinary Incontinence in a Peruvian Public Hospital
Urinary Incontinence, Urinary Incontinence, Stress
Not yet recruiting
Trial of NASHA Dx Urethral Bulking System
Urinary Incontinence, Urinary Incontinence (UI)
Enrolling by invitation
Magnetic Stimulation as a Treatment for Female Urinary Incontinence
Stress Urinary Incontinence, Urgency Urinary Incontinence
Not yet recruiting
Synchronized Core-Pelvic Floor Activation in Urinary Incontinence
Urinary Incontinence,Stress, Stress Urinary Incontinence
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
7 sites in 3 countries: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Pudendal neuromodulation in people with Mixed Urinary Incontinence and Stress Urinary Incontinence (SUI), run by Amber Therapeutics Ltd at 7 sites in 3 countries.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 9 inclusion and 32 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 15 May 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 7 sites in Belgium, United Kingdom, Netherlands. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Amber Clinical Affairs (08000418515, AURA-4X@amber-tx.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Summative rates of procedural and device related adverse events and device deficiencies. (time frame: 12 months). The study lists 3 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 15 May 2026.